logo
Share SHARE
FONT-SIZE Plus   Neg

Corcept Therapeutics Q4 Loss Widens

Corcept Therapeutics Inc. (CORT: Quote) reported a fourth-quarter net loss of $9.9 million, or $0.12 per share, compared to a net loss of $7.1 million, or $0.10 per share, for the fourth quarter of 2010.

Research and development expenses increased to $6.6 million, from $4.7 million in the year ago quarter.

During the comparable periods, research and development expenses increased primarily due to higher costs associated with the submission and prosecution of our NDA for Korlym, purchase of Korlym's active pharmaceutical ingredient, manufacture of Korlym tablets and manufacturing development activities.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Snapchat created a furor after dropping the Best Friends feature which allowed users to see who their contacts had been sharing snaps with the most. But the ephemeral messaging service provider soon vowed to reinstate the feature to assuage users who said Best Friends helped them ensure fidelity. Chinese e-commerce giant Alibaba reported a 28 percent drop in third-quarter profit, hurt by stock-based compensation expense and other costs. Meanwhile revenues surged 40 percent, driven by growth in China commerce retail business, though not at the rate analysts expected, even as its active user base ballooned. Alibaba shares dropped 9% on the NYSE. McDonald's has announced its Chief Executive Office Don Thompson will be "retiring" at the age of 51, after two tumultuous years on the job. It will instead be up to Steve Easterbrook, 48, McDonald's chief brand officer, to reverse a downturn in fortunes for the iconic hamburger chain. His challenges...
comments powered by Disqus
Follow RTT